Defunct Company
Total Trials
3
As Lead Sponsor
As Collaborator
0
Total Enrollment
38
NCT04592484
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors
Phase: Phase 1/2
Role: Lead Sponsor
Start: Sep 15, 2020
Completion: Dec 23, 2022
NCT05156229
A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).
Phase: Phase 1
Start: Sep 6, 2021
Completion: Aug 24, 2022
NCT05375604
A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC)
Start: Jun 28, 2022
Completion: May 30, 2023